Restoration of thalidomide-induced inhibition of FLK-1 expression by antisense-MO for nSMase
Experimental condition . | High FLK-1 expression, % (no.) . | Low FLK-1 expression, % (no.) . | No. embryos . |
|---|---|---|---|
| Uninjected embryos | 100 (41) | 0 (0) | 41 |
| nSMase invert-MO | 95 (40) | 5 (2) | 42 |
| nSMase antisense-MO | 71 (32) | 29 (13) | 45 |
| Uninjected embryos + thalidomide treatment | 5 (2) | 95 (39) | 41 |
| nSMase invert-MO + thalidomide treatment | 13 (5) | 87 (35) | 40 |
| nSMase antisense-MO + thalidomide treatment | 70 (40) | 30 (17) | 57 |
Experimental condition . | High FLK-1 expression, % (no.) . | Low FLK-1 expression, % (no.) . | No. embryos . |
|---|---|---|---|
| Uninjected embryos | 100 (41) | 0 (0) | 41 |
| nSMase invert-MO | 95 (40) | 5 (2) | 42 |
| nSMase antisense-MO | 71 (32) | 29 (13) | 45 |
| Uninjected embryos + thalidomide treatment | 5 (2) | 95 (39) | 41 |
| nSMase invert-MO + thalidomide treatment | 13 (5) | 87 (35) | 40 |
| nSMase antisense-MO + thalidomide treatment | 70 (40) | 30 (17) | 57 |
Whole-mount in situ mRNA hybridization for FLK-1 in trunk blood vessels of embryos was performed at 30 hpf after injection with nSMase antisense- or invert-MO in the presence or absence of 800 μM thalidomide at 8 hpf. The densities of FLK-1 expression showing more than and lower than 75% of average of uninjected control were assessed as high and low expression, respectively.